Company intelligence / Profile preview

Satiogen Pharmaceuticals, Inc.

San Diego, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Satiogen discovered a mechanism of action for treating type 2 diabetes and obesity. The company had clinical trials pending for its drug candidates targeting NTCP and TGR5.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

maralixibat

Phase 3

Indications: Progressive familial intrahepatic cholestasis, Alagille syndrome, Biliary atresia

1 more asset in the full pipeline.

Request access →

Partnerships

Mirum Pharmaceuticals (prior to acquisition)Shire/Takeda

Beyond the preview

Go deeper on Satiogen Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Satiogen Pharmaceuticals, Inc..

Explore the full profile